Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 125.00 13,296 08:01:40
Bid Price Offer Price High Price Low Price Open Price
120.00 130.00 127.50 125.00 127.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 3.90 -1.07 -3.20 32
Last Trade Time Trade Type Trade Size Trade Price Currency
16:02:38 O 3,930 126.90 GBX

Fusion Antibodies (FAB) Latest News

More Fusion Antibodies News
Fusion Antibodies Investors    Fusion Antibodies Takeover Rumours

Fusion Antibodies (FAB) Discussions and Chat

Fusion Antibodies Forums and Chat

Date Time Title Posts
12/6/202112:07☆ Fusion Antibodies: from discovery to Clinical supply ☆1,221
28/10/202014:27NEW FAB Fusion Antibodies The Next AVCT53
18/9/202015:23Fusion Antibody II51
08/2/201221:34Fabio Capello Resigns.......9

Add a New Thread

Fusion Antibodies (FAB) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Fusion Antibodies trades in real-time

Fusion Antibodies (FAB) Top Chat Posts

Fusion Antibodies Daily Update: Fusion Antibodies Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 125p.
Fusion Antibodies Plc has a 4 week average price of 120p and a 12 week average price of 120p.
The 1 year high share price is 250p while the 1 year low share price is currently 67.50p.
There are currently 25,818,278 shares in issue and the average daily traded volume is 47,963 shares. The market capitalisation of Fusion Antibodies Plc is £32,272,847.50.
whatsthepoint: It's worth many many many multiples of the current crazy share price. Wake up world.
whatsthepoint: That's of no relevance now as we seem to have had a big sell that will be disclosed in about an hour hence the big drop in the offer. MM in total control of this share price. For the time being. They can move it wherever they like.
whatsthepoint: All today's trades are buys. And still more cheap stock available. The true value of this company is not yet being reflected in the share price. All we have at the moment is when someone sells the market makers just offers them out cheaply to keep a closed book. When someone buys a few they raise the bid quickly to encourage some sellers to get the back. But when real updates and news arrives the price will just move drastically higher as market makers will not have any stock and won't want to get caught short.
whatsthepoint: Wouldn't want to be out of this now. The assays for the Covid-19 antibodies are setup so all geared up for testing.Just imagine the excitement on Belfast now. Maybe that's why the share price was perking up last week
whatsthepoint: Market makers have turned off the electronic trading platform so everything is going to NT trades unless you want to buy 50 shares. If you want to buy 3000 shares then you can phone in and buy these as the broker quoting 162 has to honour that quote. But they know very few people bother to phone their broker to buy and sell as it's more expensive for telephone trades. They are doing this to stop this share price rising. In my honest opinion.
superg1: It's why Fusion has longevity where test driven or co point parts Covid hope shares are on borrowed time. Antibody engineering type companies are a relatively new science. It seemed mad when Roche bought Genentech for $47 bill on a big premium. But they were right as the drugs they had grew in revenue EG over $20 bill of sales in 2018 alone. 7 of the top 10 drugs are now antibody related. The big names are snapping up the smaller Antibody engineering type companies. FAB seem to be a leader in the sector with and seriously impressive platform. So for me the Covid side has the potential to see a material share price hike short term, but the likely outcome, judging by what is going on in this sector, is that Fab will be acquired by a major. There is no better time to have a flag waving in Antibody engineering and skills. Fab were and are working with MAB discovery. MAB have since been acquired by BioNtech. FAB have made some big claims, a check of information available suggest they have every right to make the claims and expect the platform and their tech to be of enormous value. What is missing here is the herd jumping up and down about the share which they will probably know every little about, if they ever arrived. That's probably due to FAB being relatively quiet, not popping up in the usual interviews post every piece of news.
tidy 2: Are Fusion on a pathway to finding the Holy Grail ?Fusion rapidly advancing their R&D MAL validation programme with successful SARS-CoV-2 antigens created for commercial use, moving onto the next step, finding a neutralising antibody for the disease.I meant to cover the news from Fusion Antibodies (FAB) last week when it was announced but the news landed whilst I was under the knife having my 5th, yes 5th eye operation ! Long story but I seem to be on the mend however my surgeon would probably be slapping my wrist if she knew I was at the PC right now !You can read more in-depth info on Fusion in my research notes Part 1 and Part 2 and it's well worth a read as even though the recent news was COVID related, that element is just one part of what the company are doing but obviously topical !The share price saw a whopping 180% intraday rise on the news that the company have produced SARS-CoV-2 spike proteins (antigens) that 100% correlate with patient blood samples for the disease and at the 250p intra-day high the share price was 150% up from the share price at the time I produced my research note back in May – not a bad return thus far!The following is an extract from the RNS...The Company's extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests. The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.But the next phase of what they are doing gets even better...The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidatesThis last bit is of major interest, as I covered in my research note, the company are running an R&D programme to validate the Mammalian Antibody Library, the 'MAL' which has been in development for a few years.The opportunity...With the first few steps complete and successful if they can now use the MAL to identify neutralising antibodies for the high quality 100% correlated COVID spike proteins they have produced, the potential for a treatment for COVID that could stop the virus in its tracks would be HUGEWhilst the wider market seems to focus just on testing Pharma stocks, Fusion are at the heart of testing, diagnostics and potentially a treatment. Clearly the upside would be huge, caveated by the usual inherent complexities of drug development of course.As I have explained before though, Fusion aren't just about COVID-19, validation of the MAL would open opportunities in oncology and other healthcare applications and imagine if a large Pharma company wanted to snap up this technology for themselves to give them a firm competitive edge in getting to market faster.One can only wonder what such technology would be worth either outright or licensed to Pharma companies – either way I believe successful MAL validation opens the door for a potential $billion+ valuation.Given the company have a core business and this year returned 79% YOY revenue growth I see an excellent risk vs reward here with potentially transformative upside on offerhTTps://
29palms: FAB share price on 17th Sept - 92.5p FAB share price on 18th Sept - 182.5p FAB RNS released @ 9:31am on 18th Sept and super Self Aggrandiser appears here @ 10.12am after rise in sp True to form the super Self-Aggrandiser only ever appears on a BB thread once the share price goes stratospheric.
superg1: Shareman Well that's all down to supply and demand of the shares and often doesn't relate to the value fo the company. I see underlying value here in the growing business to justify the share price. So the MC is about £50m. In 15 PE terms it's 59p on the share price for every £1m profits which equates to about £3.4 mill profit at £2 per share. Some Covid shares have tests, some tests strips, some in trials for symptoms reduction, some vaccine options. None I can think of have Covid neutralising options. Vaccines are fine but they are telling us immunity doesn't last. We have ha various scares, on other viruses. That is what FAB is all about a library to combat various viruses and added to exiting drugs to advance those. EG the world biggest seller at $20 bill year is an antibody type drug. So imo FAB had growth, low spending and huge revenue potential via the library and the platform including carrels in drugs already as yet not identified, 1 at least in stage 2.
superg1: XTomo The way I see it with FAB is that the underlying business is exciting and was before Covid appeared, it's just that Covid caused me to look. Typically I jog on on most companies especially Bios but I like the look of Fab. As posted a 15 PE equates to about 57p on the share price per £1m profit. There was a 79% increase re you revenues. The forecast was £3m revenue the actual was £3.9m Covid has now serials highlighted the crucial roll companies like Fab play. As stated they have a good brand reputation as 5 other companies failed to provide what a Pharma needed but FAB sorted it no problem. Fab are also working with a company created by Ex Roche bosses re the library as in news. FAB do not have the high spend re drugs trials, they ditched that business plan years ago. Sop far less risk but huge upside available makes it bio I like. In a sector where it's growing in interest and profit it enhances existing treatments in various sectors.
Fusion Antibodies share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Fusion Ant..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210613 05:30:14